Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer

28 Dec 2019

Abstract excerpt

DNA abnormalities are used in inclusion criteria of clinical trials for treatments with specific targeted molecules. MYC is one of the most powerful oncogenes and is known to be associated with triple-negative breast cancer (TNBC). Its DNA amplification is often part of the targeted DNA-sequencing panels under the assumption of reflecting upregulated signaling. However, it remains unclear if MYC DNA amplification...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Genomics and Chromatin Dynamics
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31905596
DOI: 10.3390/ijms21010217

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast CancerPMID 31905596Read ↗

Characteristics of MYC Amplification and Their Association with Clinicopathological and Molecular Factors in Patients with Breast Cancer.Semantic proximity Read ↗

MYC-Driven Pathways in Breast Cancer SubtypesSemantic proximity Read ↗

Somatic gene mutation analysis of triple negative breast cancers.Semantic proximity Read ↗

Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progressionSemantic proximity Read ↗

Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.Semantic proximity Read ↗

Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumorsSemantic proximity Read ↗

CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.Semantic proximity Read ↗

Research advances and new challenges in overcoming triple-negative breast cancerSemantic proximity Read ↗

High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting.Semantic proximity Read ↗

Clinical implications of molecular heterogeneity in triple negative breast cancer.Semantic proximity Read ↗

Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer.Semantic proximity Read ↗

Identification of biomarker associated with Trop2 in breast cancer: implication for targeted therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.